Roswell Park Cancer Center

Researchers Uncover New Role for Tamoxifen in Triple-Negative Breast Cancers Roswell Park team identifies first known prognostic marker for these aggressive tumors

TNBC tumors lack 3 key receptors that existing therapies target Team led by Dr. Gokul Das focused on a different receptor, ER-beta They demonstrate that tamoxifen may be effective against many TNBC tumors. One of the mechanisms that makes so-called triple-negative breast cancer (TNBC) notoriously aggressive and hard to treat is its ability to disarm proteins that suppress tumors and mutate them in... »

Roswell Park Workforce Swells to Record Level with Latest Slate of Hires and Promotions

The team at Roswell Park Comprehensive Cancer Center has reached record levels, growing to a workforce of more than 3,500. The latest appointments announced by Roswell Park President and CEO Candace S. Johnson, PhD, and her senior leadership team mark a milestone for the 121-year-old cancer center, reflecting expansion across all areas of operations, from clinical care and education to new frontie... »

Roswell Park Reports New Path to Overcoming Drug Resistance in HER2-Positive Breast Cancer

The HER2 protein, which encourages the growth of cancer cells, is present in about 20% of all breast cancers. While HER2-positive breast cancers tend to be very aggressive, today the prognosis is generally very good, thanks to the introduction of HER2 inhibitors such as trastuzumab (brand name Herceptin). However, not all HER2-positive breast cancers respond to existing HER2 inhibitors. A renderin... »